Bill Hall, CEO & Co-Founder, Triangulate Labs
In an interview with Invest:, Bill Hall, CEO and co-founder of Triangulate Labs, discussed how AI-powered technology is revolutionizing early skin cancer detection, emphasized Skinmap’s ability to make high-quality total body photography accessible through affordable mobile technology, and said that collaborations with institutions like Mayo Clinic validate its clinical efficacy. “These collaborations drive insights into product usability and skin evolution, paving the way for broader applications and improved health outcomes,” Hall said.
What is your general overview of how Triangulate Labs is leveraging AI and technology through its app to advance skin cancer detection and prevention?
Triangulate Labs is leveraging AI-powered total body photography (TBP) through its mobile app, Skinmap, to detect skin cancer early—when it’s 99% curable. Skin cancer claims a life every four and a half minutes. Skinmap, using an iPhone Pro Max 16 with a ring light (under $1,500), captures 300 high-quality images in 60 seconds. Our patented AI maps images onto a 3D body model, comparing prior and current scans to highlight changes and support dermatologist accuracy.
Of the 110 million high-risk Americans, only 12 million see a dermatologist annually, leaving nearly 100 million without access. Skinmap aims to bridge this gap by extending dermatologists’ reach to primary care providers, specialists, and remote patients, helping filter high-risk cases for early intervention. Unlike slow mobile apps or single-lesion AI tools, Skinmap scans the entire body to flag concerning lesions. The ABCDE mnemonic (Asymmetry, Border, Color, Difference/Diameter, Evolution) guides detection, with Skinmap uniquely tracking evolution, which is critical for identifying lesions that are growing or changing. Existing solutions, like expensive booths, are economically impractical, and mobile apps disrupt clinic workflows.
To what extent are partnerships and collaborations, such as with institutions like Mayo Clinic, important in expanding the use and impact of the app?
Collaborations with academic and clinical partners are essential. Dermatology clinics not only use and fund Skinmap but also provide crucial feedback. The collaboration with Mayo Clinic and others will help validate our AI’s diagnostic accuracy. These collaborations drive scientific research skin evolution, support FDA clearance, and open opportunities for broader applications such tracking psoriasis, eczema or even systemic diseases.
In what ways is Skinmap being adopted by patients, doctors, and clinics?
Currently offered exclusively through dermatology clinics, Skinmap is well-received by dermatologists and patients alike. Just months after its commercial launch, we believe Skinmap has become the most widely used method for total body photography in the US. Dermatologists learn about total body photography and its value during their education and residency. They just don’t know how to offer it cost effectively and quickly. When they realize what we have with Skinmap, many are excited and want to use it. The problem isn’t getting interest; it’s onboarding them quickly and efficiently.
About 95% of patients offered Skinmap during their total body skin examination opt in. It is typically covered by insurance. The medical assistant or nurse collects the Skinmap in about a minute. At follow-up visits, practices often have patients arrive early for another map. This allows the dermatologist to compare maps during the exam to see changes. A lesion that is borderline but not changing can be monitored. Rapidly changing lesions that might be overlooked in a regular exam gain extra attention that may lead to biopsy. Some cancers found this way wouldn’t have been caught otherwise.
What is your outlook for Triangulate Labs and Skinmap over the next two to three years, and how are you looking to expand or introduce new services within the app?
Triangulate Labs is working toward FDA approval for a diagnostic AI version of Skinmap that could be used in non-specialist settings, such as primary care. This would enable early screening for the 100 million Americans at high risk for skin cancer who don’t currently see dermatologists, catching skin cancer earlier and improving survival rates. Expansion beyond dermatology clinics aims to save lives by improving early detection access and is a strategic priority.
What is your outlook on the healthcare innovation industry in Palm Beach, and are there other notable innovations or examples you are seeing in the area?
South Florida, especially FAU’s Research Park, is a hub for dermatology and healthcare innovation. ModMed, a Research Park alum, recently had a multibillion dollar transaction, employing thousands with its medical software. Global Ventures at FAU, where we’re based, hosts innovative companies like Thema Brain Health, advancing Alzheimer’s research. The region’s abundant sunshine and high skin cancer rates make it ideal for dermatology-focused businesses like ours. The population’s needs drive demand, and the presence of numerous dermatologists fosters collaboration. While we’re focused on keeping customers happy and developing Skinmap, the vibrant ecosystem, including fundamental research companies, supports our mission to combat skin cancer effectively.
